XBiotech: Jumps on collaboration to develop COVID-19 treatment

XBiotech

06/04/2020 12:06

** Shares of drug developer  XBIT.O  rise 16.2% to $13.35
premarket - among top pct gainers across U.S. exchanges
    ** XBIT has developed a test that can help BioBridge
Global's unit, QualTex Laboratories, identify the antibodies in
human blood that work against the virus that causes COVID-19
 urn:newsml:reuters.com:*:nGNE84GG9b
    ** The companies are participating in an FDA program for
U.S. blood centers to collect and distribute convalescent plasma
from individuals who have recovered from COVID-19  urn:newsml:reuters.com:*:nGNE84GG9b
    ** South Texas Blood & Tissue Center will provide XBIT with
blood samples to help it develop an antibody therapy for the
disease
    ** Stock fell 38.4% YTD, as of last closeS

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))